key: cord-0336033-dcj2x59e
authors: MARQUETTE, C. H.; MARTINUZZI, E.; BENZAQUEN, J.; GUERIN, O.; LEROY, S.; SIMON, T.; ILIE, M.; HOFMAN, V.; ALLEGRA, M.; TANGA, V.; MICHEL, E.; BOUTROS, J.; MANIEL, C.; SICARD, A.; GLAICHENHAUS, N.; CZERKINSKY, C.; BLANCOU, P.; HOFMAN, P.
title: A Single Dose of COVID-19 mRNA Vaccine Induces Airway Immunity in COVID-19 Convalescent Patients
date: 2021-12-17
journal: nan
DOI: 10.1101/2021.12.16.21267932
sha: 8f181816028bcdadf845c461adc11a5068934de6
doc_id: 336033
cord_uid: dcj2x59e

Background: Mucosal antibodies can prevent virus entry and replication in mucosal epithelial cells and hence virus shedding. Preclinical and clinical studies have shown that a parenteral booster injection of a vaccine against a mucosal pathogen promotes stronger mucosal immune responses following prior infection compared to two injections of a parenteral vaccine. We investigated whether this was also the case for a COVID-19 mRNA vaccine. Methods: Twenty-three COVID-19 convalescent patients and 20 SARS-CoV-2-naive subjects were vaccinated with respectively one and two doses of the Pfizer-BioNTech COVID-19 RNA vaccine. Nasal Epithelial Lining Fluid (NELF) and plasma were collected before and after vaccination and assessed for Immunoglobulin (Ig)G and IgA to Spike and for their ability to inhibit the binding of Spike to its ACE-2 receptor. Blood was analyzed one week after vaccination for the number of Spike-specific Antibody Secreting Cells (ASCs) with a mucosal tropism. Results: In COVID-19 convalescent patients, a single dose of vaccine amplified pre-existing Spike-specific IgG and IgA antibody responses in both NELF and blood against both vaccine homologous and variant strains, including delta. These responses were associated with Spike-specific IgG and IgA ASCs with a mucosal tropism in blood. Nasal IgA and IgG antibody responses were lower in magnitude in SARS-CoV-2-naive subjects after two vaccine doses Conclusion: This study showed that a parenteral booster injection of a COVID-19 RNA vaccine promoted stronger mucosal immune responses in COVID-19 convalescent patients compared to SARS-CoV-2 naive subjects who had received a first vaccine dose.

Amid the surge of variants of concern, most COVID-19 vaccines are highly effective against hospitalization and death of patients caused by a variety of SARS-CoV-2 strains (1) (2) (3) (4) . Early studies performed before the emergence of the delta variant showed that individuals who were fully vaccinated with an mRNA vaccine were less likely than unvaccinated persons to be infected with SARS-CoV-2 or to transmit it to others (5, 6) . Likewise, with the delta variant, studies have shown that vaccination reduces the risk of infection. Nonetheless, fully vaccinated individuals with breakthrough infections still transmit infection, including to fully vaccinated contacts (7) . Therefore, the risk of a SARS-CoV-2 breakthrough infection in fully vaccinated people cannot be eliminated as long as there is continued transmission of the virus.

Protection from severe forms of COVID-19 in fully vaccinated adults is mediated, at least in part, by SARS-CoV-2-specific antibodies, as demonstrated by the transfer of plasma from COVID-19 convalescent individuals to recently infected patients (8) . However, the immune mechanisms that prevent carriage and shedding of SARS-CoV-2 remain to be elucidated. Lessons drawn from other mucosal pathogens suggest that mucosal antibodies and especially secretory immunoglobulin A (sIgA) can efficiently block transmission of respiratory viruses (9) . Relevant to this issue, SARS-CoV-2-specific humoral responses are dominated by IgA and peripheral expansion of IgA ASCs with a mucosal homing potential occurs shortly after disease onset (10) . Further, sIgA are substantially more potent than bone marrow-derived serum monomeric IgA and IgG at neutralizing SARS-CoV-2 (11) . As for Spikespecific IgA induced by mRNA COVID-19 vaccines, these antibodies are detected in SARS-CoV-2-naive individuals in plasma (10) , milk (12) , saliva (13) and nasal fluids (14) as early as two weeks after vaccination and for up to 6 months.

A dominant concept in vaccinology is that mucosal immunity is more efficiently induced by mucosal (ex. nasal or oral) administration of vaccines than by parenteral injection and that mucosal immune memory wanes more rapidly than systemic immune memory (12, 13) . On a related topic, we and others have shown that a single booster injection of inactivated poliovirus vaccine boosted mucosal immune responses and reduced virus shedding in individuals previously vaccinated with an oral live polio vaccine (14) . Building on these results, we hypothesized that immunization by parenteral injection with a COVID-19 mRNA vaccine might be more All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Forty-three otherwise healthy subjects (23 SARS-CoV-2 naive and 20 COVID-19 convalescent patients) were included in a prospective monocentric longitudinal study between April 14, 2021 and June 15, 2021 at the Nice University Hospital (Nice, France). The participants who recovered from a SARS-CoV-2 infection had a history of mild or moderate COVID-19 three months or more before inclusion. These subjects will be referred thereafter as Covid + while the others will be referred as Covid -. While all subjects received one injection of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) on day 0, only Covidsubjects received a second injection of the BNT162b2 mRNA COVID-19 vaccine on day 21, as recommended by the French National Health Authority (15) . Blood was collected on day 0, 7 and 21 from all subjects, and NELF were collected on day 0 and 21 from all subjects and on day 28 and 42 for Covid-subjects (Supplementary Figure 1) . All samples were centralized and stored in our Biobank (16) . All subjects signed an informed consent to participate in this work. The study was approved by the CPP Sud Méditerranée V ethics committee. ClinicalTrial.gov identifier: NCT04418206. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

IgA and IgG levels reacting to the SARS-CoV-2 Spike protein, the SARS-CoV-2 IgG. Data were acquired on the V-PLEX® Sector Imager 2400 plate reader and analyzed using the Discovery Workbench 3·0 software (MSD). Standard curves were generated using standards provided in the kit. Serial 4-fold dilutions of the standards were run to generate a 7-standard concentration set, and the diluent alone was used as a blank. The percentage inhibition was calculated according to the manufacturer's instructions. This assay has been shown to correlate with assays for viral neutralization.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To test whether the nasal mucosal IgA responses differed between COVID-19 convalescent subjects and SARS-CoV-2-naive subjects, and more specifically to test whether these two groups differed in the proportion of IgA-producing ASCs with a mucosal tropism in blood, we used an antigen-specific ELISpot assay to measure the number of ASCs producing Spike-specific IgA or IgG after prior enrichment of CD38expressing cells. Since mucosal ASCs preferentially express tissue specific cell surface homing markers, we also partitioned ASCs expressing integrin Next, a mixture of appropriately diluted goat antibodies to human IgA and IgG, respectively labelled with alkaline phosphatase and horseradish peroxidase (Southern Biotech) was added to the wells. Zones of solid phase-bound secreted IgA and IgG antibodies were visualized by stepwise incubation with corresponding enzyme chromogen substrates. After drying, plates were scanned and blue (IgA) and red (IgG) spots enumerated using an automated ELISPOT reader. Total and nominal mucosal ASCs as well as ISCs were enumerated against each SARS-CoV-2 Spike antigen and net ASC and ISC counts were determined after subtracting corresponding non-specific counts detected in control (BSA-coated) wells. Data are expressed as the ASC or ISC number per millilitre of blood.

Data are presented as geometric means and 95% confidence intervals of geometric means with a standard error of the mean (SEM) and medians with interquartile ranges (IQR) for quantitative variables, or as numbers and percentages for All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. GraphPad Prism 9·0 (GraphPad Software, Inc., San Diego, CA). Differences were considered significant when the p-value was < 0·05. For a multivariate analysis, a logistic regression using seroconversion as the outcome and risk factors as independent variables was performed. Logistic regressions were conducted in R (R Core Team, 2020). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We enrolled COVID-19 convalescent PCR-negative patients (n=20) who had been infected with SARS-CoV-2 before the emergence of the delta variant and SARS-CoV-2-naive seronegative subjects (n=23). Subjects in the two groups did not differ in age, gender, Body Mass Index (BMI), and total number of blood leukocytes, lymphocytes and neutrophils (Supplementary Table 1 IgA in NELF are produced by a subpopulation of CD38 + ASCs that migrate to the nasal mucosa where they release dimeric IgA. Because the IgA responses in nasal secretions were different in COVID-19 convalescent patients compared to SARS-CoV-2-naive subjects, we hypothesized that these two groups differed in the total number of IgA-producing ASCs in blood, and more specifically in the proportion of IgA-producing ASCs with a mucosal tropism. To test this, we used an antigen-All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 17, 2021. ; https://doi.org/10.1101/2021.12.16.21267932 doi: medRxiv preprint -10 -specific ELISpot assay to measure the number of ASCs producing Spike-specific IgA or IgG in blood after prior enrichment of CD38-expressing cells. Because mucosal ASCs preferentially express tissue specific cell surface homing markers, we also partitioned ASCs expressing the integrin β 7, which have been proposed to promote the migration of ASCs toward mucosal tissues such as the intestinal mucosae. ASCs producing Spike-specific IgA or IgG were neither detected before vaccination, nor in SARS-CoV-2-naive subjects 7 days after the first vaccine dose (not shown). In contrast, these cells were readily detected after enrichment for both CD38 + and β 7 + cells in both COVID-19 convalescent patients and vaccine-primed SARS-CoV-2naive subjects after they have received a vaccine dose. The proportion of β 7 + cells among CD38 + was higher in the first group compared to the second one, suggesting an increased proportion of ASCs with a tropism to mucosal tissues ( Figure 3 ). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

In keeping with our initial hypothesis, we found that both the level of Spike-specific IgG and IgA in NELF, the proportion of responders and the ability of NELF antibodies to inhibit the binding of Spike to ACE-2 was higher in COVID-19 convalescent subjects than in vaccine-primed SARS-CoV-2 naive subjects. Further, the proportion of ASCs with a mucosal tropism was higher in COVID-19 convalescent subjects after one vaccine doses compared to SARS-CoV-2 naive subjects after two vaccine doses. 

lymphoid tissue (NALT) and regional LN, respectively. In COVID-19 convalescent patients, the injection of a single dose of COVID-19 mRNA vaccine induced memory B cells to differentiate into ASCs with a preferential tropism to mucosa. In contrast, in All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 17, 2021. ; https://doi.org/10.1101/2021.12.16.21267932 doi: medRxiv preprint -12 -vaccine-primed SARS-CoV-2-naive subjects, the injection of a second vaccine dose induces B cells to differentiate into ASCs, which are less prone to home to the mucosa. In line with this hypothesis, we found that the proportion of ASCs with mucosal tropism was higher in COVID-19 convalescent patients after the injection of a single vaccine dose compared to SARS-CoV-2-naive subjects after they received two doses.

The inhibition of binding of Spike to ACE-2 by NELF and antibodies in plasma is mediated by RBD-specific IgG and IgA. In keeping with the higher levels of RBDspecific IgG and IgA in COVID-19 convalescent patients compared to vaccine-primed SARS-CoV-2-naive individuals, the inhibition of binding by antibodies in plasma and NELF at baseline was higher in the first group compared to the second one. This was observed for the Wuhan parental strain and its variants including delta. Vaccination further increased inhibition of binding in COVID-19 convalescent patients compared to vaccine-primed subjects. Of note, inhibition of binding by antibodies in plasma was higher in COVID-19 convalescent patients after vaccination compared to SARS-CoV-2 naive subjects after vaccine priming and boosting. While this latter result may appear surprising considering that patients from these two groups exhibited similar amounts of RBD-specific IgG and IgA in plasma, the explanation may lie in the possibly that these antibodies were present in saturating amounts in the assay for inhibition of binding.

The present study has some limitations. Firstly, our study sample consisted of a small cohort of COVID-19 convalescent patients and SARS-CoV-2-naive subjects. Therefore, our results need to be validated with a larger and independent cohort of patients. Further, only 11 Covidsubjects were sampled after the second vaccine 

The authors declare no competing interests.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The data that support the findings of this study are available from NG. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Levels of IgG and IgA to the indicated antigens in Covidand Covid + subjects before and after vaccination were compared using a two-tailed Wilcoxon-Mann-Whitney test.

n.s., not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. inhibition of binding in Covidand Covid + subjects before and after vaccination were compared using a two-tailed Wilcoxon-Mann-Whitney test. n.s., not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Blood of Covidsubjects taken on day 28 and Covid + subjects on day 7 were analysed for the number of Spike-specific IgA-and IgG-secreting cells in individual subjects after enrichment of CD38 + and β 7 + cells. The proportion of β 7 + ASCs in the two groups were compared using a two-tailed Wilcoxon-Mann-Whitney test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 17, 2021. ; https://doi.org/10.1101/2021.12.16.21267932 doi: medRxiv preprint

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Effectiveness of Covid-19

Vaccines against the B.1.617.2 (Delta) Variant

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Effect of Vaccination on Transmission of SARS-CoV-2

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Multi-faceted functions of secretory IgA at mucosal surfaces

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG

Publisher Correction: Mucosal vaccines -fortifying the frontiers

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted

Mucosal vaccines -fortifying the frontiers

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus

French National Health Authority FNH, HAS ed

Establishment of a Collection of Blood-Derived Products from COVID-19

Experience of the LPCE Biobank

Collection of nasal secretions for immunological analysis

Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood

Designed for Anti-Microbial Defense

All rights reserved. No reuse allowed without permission

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted

Supplementary were computed. Differences between groups were considered to be statistically significant when corrected p-values were < 0.05. n.s.; not significant. and for plasma and NELF on day 42. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Levels of IgG and IgA to the indicated antigens in Covidand Covid + subjects before and after vaccination were compared using a two-tailed Wilcoxon-Mann-Whitney test.n.s., not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The percentage of inhibition of binding in Covidand Covid + subjects before and after vaccination were compared using a two-tailed Wilcoxon-Mann-Whitney test. n.s., not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.